AM-168
HER3‑driven resistance in breast and lung cancer
PreclinicalActive
Key Facts
Indication
HER3‑driven resistance in breast and lung cancer
Phase
Preclinical
Status
Active
Company
About AcadeMab Biomedical
Taiwan biotech integrating antibody and mRNA‑LNP technologies to target oncology and infectious disease unmet needs.
View full company profile